Alternative Therapy of Menopausal Syndrome from the Perspective of Comprehensive Aging Prevention

Aim. To systematize data on optimal forms of delivery of the resveratrol molecule, its dosages, bioavailability, combined regimens and possible side effects when used to slow down aging in women during the menopausal transition.

Key points. Every year in the Russian Federation, more than 1 million women enter menopause. Climacteric syndrome as a complex of vasomotor, psychoemotional, musculoskeletal disorders due to estrogen deficiencyleads to a decrease in the quality oflife of women over 40 years old. Within the framework of the review article, an assessment of modern non-hormonal methods for correcting climacteric syndrome was carried out. Among the new generation of phytoestrogens, trans-resveratrol stands out significantly; we considered the multitarget properties of the molecule from the standpoint of slowing down aging.

Conclusion. The use of phytoestrogens has wide possibilities in personalized menopausal phytotherapy, the strategy of increasing the bioavailability of new phytotherapy technologies is able to influence estrogen-deficient conditions of women with greater efficiency. Trans­resveratrol in sublingual form is a unique solution for the correction of climacteric syndrome due to its high bioavailability, in this form it bypassesliver metabolism. The ability of trans-resveratrol to modulate estrogen-dependent pathways, suppress oxidative stress and systemic inflammation allows to effectively reduce the severity of vasomotor symptoms, improve cognitive functions and slow down involutional processes. Sublingual administration ensures rapid achievement of therapeutic concentrations and potentiates geroprotective effects, which makes this form of the drug promising for complex anti-aging therapy in women in menopause.

1. Lambrinoudaki I., Armeni E., Goulis D., Bretz S. et al. Menopause, wellbeing and health: a care pathway from the European Menopause and Andropause Society. Maturitas. 2022;163:1–14. DOI: 10.1016/j.maturitas.2022.04.008

2. Menopausal hormone therapy: interdisciplinary problem — joint solution. Innovative Pharmacotherapy. 2024;6(24):16–24. (in Russian)

3. Panay N., Palacios S., Davison S., Baber R., Women’s perception of the menopause transition: a multinational, prospective, communitybased survey. GREM. 2021;2(3):178–83. DOI: 10.53260/GREM.212037

4. Di Stasi V., Verde N., Maseroli E., Scavello I. et al. Female sexual dysfunction as a warning sign of chronic disease development. Curr. Sex. Health Rep. 2019;11:307–19 DOI: 10.1007/s11930-019-00229-4

5. Lineva O.I., Kazakova A.V., Kazakov V.F., Spiridonova N.V. et al. Conception “4P” — medicine of the future: ways of implementation. Kremlin Medicine Journal. 2020;2:43–7. (in Russian). DOI: 10.26269/6hvq-6n25

6. Serov V.N., Yureneva S.V., eds. Algorithms for menopausal hormone therapy during the period of peri- and postmenopause. Joint position statement of RSOG RAM, AGE, RAOP experts. Obstetrics and Gynecology. 2021;3:210–21. (in Russian). DOI: 10.18565/aig.2021.3.210-221

7. Manson J.E., Aragaki A.K., Rossouw J.E., Anderson G.L. et al. Menopausal hormone therapy and long-term all-cause and causespecific mortality: the women's health initiative randomized trials. JAMA. 2017;318(10):927–38. DOI: 10.1001/jama.2017.11217

8. Alternative therapy of menopausal syndrome. Innovation to support women's health during menopause. II National Menopause Congress. Abbott Satellite Symposium. Effective Pharmacoterapy. 2021;17(19)68– 75. (in Russian)

9. Moldovanova, M.V., Marchenkova, L.A. Efficacy of a Combination of Xenon Inhalations and General Cryotherapy in the Management of Menopausal Syndrome Osteoporosis and Bone Diseases. 2024;27(S1):14–15. (in Russian). DOI: 10.14341/osteo2024271S

10. Kotenko N.V., Barashkov G.N., Salamadina G.E., Borisevich О.О. Assessment of the effectiveness of physiotherapeutic methods for management of early menopause disorders. Gynecology, Obstetrics and Perinatology. 2020;19(4):58–62. (in Russian). DOI: 10.20953/1726-1678-2020-4-58-62

11. Dahlman-Wright K., Cavailles V., Fuqua S.A., Jordan V.C. et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev. 2006;58(4):773–81. DOI: 10.1124/pr.58.4.8

12. Heldring N., Pike A., Andersson S., Matthews J. et al. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 2007;87(3):905–31. DOI: 10.1152/physrev.00026.2006. PMID: 17615392.

13. Vinokurova E.A., Ismailova D.Kh., Khvoschina T.N. New possibilities of personalised menopausal phytotherapy with resveratrol. Doctor.Ru. 2021;20(6):92–6. (in Russian). DOI: 10.31550/1727-2378-2021-20-6-92-96

14. Kareva E.N., Smetnik A.A. Estrogen-like and antioxidant properties of resveratrol in clinical pharmacology and therapeutic use. Obstetrics and Gynecology. 2021;12:37–48 (in Russian). DOI: 10.18565/aig.2021.12.37-48

15. Messina M.J., Persky V., Setchell K.D., Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer. 1994;21(2):113–31. DOI: 10.1080/01635589409514310

16. Nechuta S.J., Caan B.J., Chen W.Y., Lu W. et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am. J. Clin. Nutr. 2012;96(1):123–32. DOI: 10.3945/ajcn.112.035972

17. “The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573–90. DOI: 10.1097/GME.0000000000002200

18. Davinelli S., Scapagnini G., Marzatico F., Nobile V. et al. Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: a randomized, placebo-controlled study. Maturitas. 2017;96:77–83. DOI: 10.1016/j.maturitas.2016.11.016

19. Asensi M., Ortega A., Mena S., Feddi F. et al. Natural polyphenols in cancer therapy. Crit. Rev. Clin. Lab. Sci. 2011;48(5–6):197–216. DOI: 10.3109/10408363.2011.631268

20. Milia R. Improvement of climacteric symptoms with a novel sublingual product containing trans-resveratrol. Prog. Nutr. 201517(1):68–72.

21. Leo L., Surico D., Deambrogio F., Scatuzzi A. et al. Dati preliminari sull'efficacia del resveratrolo in una nuova formulazione nel trattamento delle hot flushes. Preliminary data on the effectiveness of resveratrol in a new formulation in treatment of hot flushes. Minerva Ginecol. 2015;67(5):475–83. (in Italian)

22. Méndez-del Villar M., González-Ortiz M., Martínez-Abundis E., PérezRubio K.G. et al. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat. Disord. 2014;12(10):497–501. DOI: 10.1089/met.2014.0082

23. Wong R.H., Raederstorff D., Howe P.R. Acute resveratrol consumption improves neurovascular coupling capacity in adults with type 2 diabetes mellitus. Nutrients. 2016;8(7):425. DOI: 10.3390/nu8070425

24. Thaung Zaw J.J., Howe P.R., Wong R.H. Long-term effects of resveratrol on cognition, cerebrovascular function and cardiometabolic markers in postmenopausal women: a 24-month randomised, double-blind, placebo-controlled, crossover study. Clin. Nutr. 2021;40(3):820–9. DOI: 10.1016/j.clnu.2020.08.025

25. Uberti F., Morsanuto V., Aprile S., Ghirlanda S. et al. Biological effects of combined resveratrol and vitamin D3 on ovarian tissue. J. Ovarian Res. 2017;10(1):61. DOI: 10.1186/s13048-017-0357-9

26. Asis M., Hemmati N., Moradi S., Nagulapalli Venkata K.C. et al. Effects of resveratrol supplementation on bone biomarkers: a systematic review and meta-analysis. Ann. N. Y. Acad. Sci. 2019;1457(1):92– 103. DOI: 10.1111/nyas.14226

27. Martiniakova M., Babikova M., Omelka R. Pharmacological agents and natural compounds: available treatments for osteoporosis. J. Physiol. Pharmacol. 2020;71(3). DOI: 10.26402/jpp.2020.3.01

28. Wong R.H., Thaung Zaw J.J., Xian C.J., Howe P.R. Regular supplementation with resveratrol improves bone mineral density in postmenopausal women: a randomized, placebo-controlled trial. J. Bone Miner. Res. 2020;35(11):2121–31. DOI: 10.1002/jbmr.4115

29. Zhu W., Qin W., Zhang K., Rottinghaus G.E. et al. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr. Cancer. 2012;64(3):393–400. DOI: 10.1080/01635581.2012.654926

30. Kolahdouz Mohammadi R., Arablou T. Resveratrol and endometriosis: In vitro and animal studies and underlying mechanisms (review). Biomed. Pharmacother. 2017;91:220–8. DOI: 10.1016/j.biopha.2017.04.078

31. Sukhikh G.T., Adamyan L.V., Dubrovina S.O., Baranov I.I. et al. Prolonged cyclical and continuous regimens of dydrogesterone are effective for reducing chronic pelvic pain in women with endometriosis: results of the ORCHIDEA study. Fertil. Steril. 2021;116(3 suppl.):E474. DOI: 10.1016/j.fertnstert.2021.08.028